Pharmacy Question for the Week of February 12, 2018

Pharmacy Compliance Question of the Week

Question:

Is Q5102 still the code to assign for an injection of the biosimilar infliximab?

Answer:

Code Q5102, which describes both currently available versions of infliximab biosimilars, is the correct code to assign but only until March 31, 2018. It will be discontinued effective for claims with dates of service on or after April 1, 2018 and will be replaced with the two codes below.

Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.